Immunovant (IMVT) Gains as Roivant Sciences Ltd. Explores Takeover
Tweet
Share
E-mailGet Alerts IMVT Hot Sheet
Down)Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Immunovant (NASDAQ: IMVT) gains 50% pre-open after Roivant Sciences Ltd. discloses in an amended 13D that it has engaged Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and SVB Leerink LLC to serve as its financial advisors in connection with the evaluation of a potential transaction involving the Issuer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ginkgo Bioworks Said to Weigh Over $20B Deal with Soaring Eagle Acquisition (SRNGU) - Bloomberg
- Cellebrite to List on Nasdaq Through Merger with TWC Tech Holdings II Corp. (TWCT)
- China set to clear Tencent's $3.5 billion Sogou (SOGO) deal subject to data security conditions - Reuters (Earlier)
Create E-mail Alert Related Categories
13Ds, Hot M&A, Mergers and Acquisitions, RumorsRelated Entities
JPMorgan, Goldman Sachs, 13D, Pre Market MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
